Management of Scalp Psoriasis
- 131 Downloads
Scalp psoriasis is a frequent expression of the common skin disease psoriasis, and scaling and itching are the two major complaints. Topical treatments are the mainstay of the treatment of psoriasis of the scalp, with the vehicle as well as the active ingredient relevant to efficacy, tolerability and compliance. Vehicles can be shampoos, lotions, gels, foams, creams and more greasy ointments. Active ingredients are keratolytics, coal tar (liquor carbonis detergens), dithranol, corti-costeroids and vitamin D3 analogues. Some effect has also been described from topical or systemic imidazole derivatives.
Topical corticosteroids remain the mainstay in the treatment of scalp psoriasis. The effects are rapid, the formulations are patient friendly and the adverse effects seem limited, although no data are available to support safety during prolonged use (more than 4 weeks).
Topical vitamin D3 analogues have been available for the treatment of psoriasis since 1992. In the lotion formulation in particular, vitamin D3 analogues are a patient friendly, tolerable and effective alternative to corticosteroids, although the effects are optimal after 8 weeks, in contrast to 2–3 weeks for topical corticosteroids. Facial irritation (often temporary) can also be a disadvantage of vitamin D3 analogues, although only a small proportion of patients stop treatment for this reason.
All other treatment options for psoriasis, such as tazarotene, phototherapy and systemic treatment with methotrexate, acitretin and cyclosporin are often not indicated or not suitable for treatment of the scalp.
In daily practice, to make a choice from the available therapeutic arsenal for psoriasis, each patient should be examined individually. Deteriorating factors have to be excluded. For scaling, keratolysis is the first step. Subsequently, active treatment can be chosen depending on the clinical picture. When the psoriatic lesions are mainly characterised by inflammation, anti-inflammatory drugs such as topical corticosteroids are indicated. When scaling is the more important clinical feature, vitamin D3 analogues are indicated.
Generally, intermittently used topical corticosteroids alternating with vitamin D3 derivatives either combined or not with liquor carbonis detergens containing shampoo is the most suitable treatment for most patients. Because psoriasis capitis is a chronic disease, long term treatment should, in addition to medical advice, also provide patient support and motivation.
KeywordsPsoriasis Topical Corticosteroid Calcipotriol Acitretin Tazarotene
- 5.Rosenberg EW, Noah PW, Skinner Jr RB, et al. Microbial associations of 167 patients with psoriasis. Acta Derm Venereol Suppl (Stockh) 1989; 146: 72–4Google Scholar
- 7.Arnold WP. Tar. In: van de Kerkhof PCM, editor. The management of psoriasis. Clin Dermatol 1997; 15: 739–44Google Scholar
- 11.Rosenberg EW, Belew PW, Skinner Jr RB. Treatment of psoriasis with antimicrobial agents. Semin Dermatol 1985; 4: 307–11Google Scholar
- 13.Galewsky E. Ueber Cignolin, ein Ersatzpraparat des Chrysarobins. Dermatol Wschr 1916; 62: 113–5Google Scholar
- 14.Mahrle G, Bonnekoh B, Wevers A, et al. Anthralin: how does it act and are there more favourable derivatives? Acta Derm Venereol (Stockh) 1994; Suppl. 86: 83–4Google Scholar
- 15.Engel DJ, Marx AF, Rekker RF, et al. Topically active cortico-steroids. A quantitative evaluation of McKenzie’s skin-blanching test. Arch Dermatol 1974; 109: 863–5Google Scholar